John M. Burke

Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma

Toni K. Choueiri, Piotr Tomczak, Se Hoon Park et al. · New England Journal of Medicine · 2021 · 746 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study

Ian W. Flinn, Richard van der Jagt, Brad S. Kahl et al. · Blood · 2014 · 638 citations · Full text

Life Sciences, Immunology, Internal Medicine +3

Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma

Umberto Vitolo, Marek Trněný, David Belada et al. · Journal of Clinical Oncology · 2017 · 424 citations

Medicine, Hematology, Oncology +12

First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study

Ian W. Flinn, Richard van der Jagt, Brad S. Kahl et al. · Journal of Clinical Oncology · 2019 · 307 citations · Full text

Medicine, Oncology, Pharmacotherapy +12

Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma

Toni K. Choueiri, Piotr Tomczak, Se Hoon Park et al. · New England Journal of Medicine · 2024 · 285 citations · Full text

Medicine, Oncology, Pharmacotherapy +17